159 related articles for article (PubMed ID: 16310700)
1. The emerging role of 18F-fluorodeoxyglucose positron emission tomography in the management of primary and recurrent rectal cancer.
Chessin DB; Kiran RP; Akhurst T; Guillem JG
J Am Coll Surg; 2005 Dec; 201(6):948-56. PubMed ID: 16310700
[No Abstract] [Full Text] [Related]
2. The metabolic response using 18F-fluorodeoxyglucose-positron emission tomography/computed tomography and the change in the carcinoembryonic antigen level for predicting response to pre-operative chemoradiotherapy in patients with rectal cancer.
Yoon MS; Ahn SJ; Nah BS; Chung WK; Song JY; Jeong JU; Nam TK
Radiother Oncol; 2011 Jan; 98(1):134-8. PubMed ID: 21040991
[TBL] [Abstract][Full Text] [Related]
3. Recent evidences of the use of 18F-fluorodeoxyglucose positron emission tomography in the management of colorectal cancer.
Dias AR; Nahas SC; Camargo EE; Nahas CS
J Surg Educ; 2007; 64(2):114-9. PubMed ID: 17462214
[TBL] [Abstract][Full Text] [Related]
4. A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients.
Moore HG; Akhurst T; Larson SM; Minsky BD; Mazumdar M; Guillem JG
J Am Coll Surg; 2003 Jul; 197(1):22-8. PubMed ID: 12831920
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
[TBL] [Abstract][Full Text] [Related]
6. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?
Staib L; Schirrmeister H; Reske SN; Beger HG
Am J Surg; 2000 Jul; 180(1):1-5. PubMed ID: 11036130
[TBL] [Abstract][Full Text] [Related]
7. DIAGNOSTIC ROLE OF FLUORINE-18 (18F) FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY IN DETECTING RECURRENT DISEASE IN PATIENTS WITH COLORECTAL CANCER AND ELEVATED CARCINOEMBRYONIC ANTIGEN.
Matovina E; Mihailović J; Nikoletić K; Srbovan D
Med Pregl; 2015; 68(11-12):376-81. PubMed ID: 26939303
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis of the postoperative local recurrence of rectal cancer by FDG-PET--a case report].
Katsumoto Y; Maruyama N; Nakamura M; Shingai T; Maruyama K; Nakaguchi K; Furukawa J; Okajima S; Sue F; Fukunaga H; Ikenaga M; Sekimoto K
Gan To Kagaku Ryoho; 2001 Oct; 28(11):1688-91. PubMed ID: 11708010
[TBL] [Abstract][Full Text] [Related]
9. [The value of positron emission tomography in the diagnosis of recurrent rectal cancer].
Lehner B; Schlag P; Strauss L; Dimitrakopoulou A; Herfarth C
Zentralbl Chir; 1990; 115(13):813-7. PubMed ID: 2238957
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study.
Langenhoff BS; Oyen WJ; Jager GJ; Strijk SP; Wobbes T; Corstens FH; Ruers TJ
J Clin Oncol; 2002 Nov; 20(22):4453-8. PubMed ID: 12431968
[TBL] [Abstract][Full Text] [Related]
11. Utility of 2-fluoro-2-deoxy-D-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels.
Liu FY; Chen JS; Changchien CR; Yeh CY; Liu SH; Ho KC; Yen TC
Dis Colon Rectum; 2005 Oct; 48(10):1900-12. PubMed ID: 15991059
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of fusion images using (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography in local recurrence of rectal cancer.
Fukunaga H; Sekimoto M; Tatsumi M; Ikenaga M; Ohue M; Seshimo I; Higuchi I; Takayama O; Yasui M; Ikeda M; Yamamoto H; Monden M
Int J Oncol; 2002 Apr; 20(4):691-5. PubMed ID: 11894111
[TBL] [Abstract][Full Text] [Related]
13. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Shandal V; Kumar R
BJU Int; 2010 Jul; 106(1):132-3. PubMed ID: 20553479
[No Abstract] [Full Text] [Related]
14. [Imaging modalities in the assessment of presacral recurrent rectal cancer].
Wang Y; Yang S
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 May; 23(5):456-460. PubMed ID: 32842424
[TBL] [Abstract][Full Text] [Related]
15. Immunoscintigraphy of local recurrent rectal cancer with 99mTc-labeled anti-CEA monoclonal antibody CL58.
Yao YF; Yang Z; Li ZF; Gu J
World J Gastroenterol; 2007 Mar; 13(12):1841-6. PubMed ID: 17465478
[TBL] [Abstract][Full Text] [Related]
16. Management of recurrent colorectal cancer with positron emission tomography.
Haji A
Br J Hosp Med (Lond); 2007 Nov; 68(11):580-3. PubMed ID: 18087843
[TBL] [Abstract][Full Text] [Related]
17. Elevated carcinoembryonic antigen and sarcoidosis masquerading as metastatic colon cancer.
Gallagher DJ; Libby DM; Kemeny N
Clin Colorectal Cancer; 2009 Jul; 8(3):172-4. PubMed ID: 19632934
[TBL] [Abstract][Full Text] [Related]
18. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer.
Gearhart SL; Frassica D; Rosen R; Choti M; Schulick R; Wahl R
Ann Surg Oncol; 2006 Mar; 13(3):397-404. PubMed ID: 16485158
[TBL] [Abstract][Full Text] [Related]
19. [High-dose-rate brachytherapy in recurrent rectal cancer after conventional recurrence treatment].
Raabe NK; Sundfør K; Hole KH; Djupvik LH; Larsen SG; Dueland S
Tidsskr Nor Laegeforen; 2014 Oct; 134(20):1929-30. PubMed ID: 25350435
[No Abstract] [Full Text] [Related]
20. Does positron emission tomography change management in primary rectal cancer? A prospective assessment.
Heriot AG; Hicks RJ; Drummond EG; Keck J; Mackay J; Chen F; Kalff V
Dis Colon Rectum; 2004 Apr; 47(4):451-8. PubMed ID: 14978612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
